Risk Factors for PICC-Related Infection in 994 High-Risk Patients: The Role of Hb Levels and Sampling Frequency

Mahidol University1,239 enrolled

Overview

This retrospective cohort study aims to evaluate the incidence and clinical predictors of Central Line-Associated Bloodstream Infections (CLABSI) in patients receiving Peripherally Inserted Central Catheters (PICCs) via the Anesthesia Department.

Study Type

OBSERVATIONAL

Enrollment

1,239

Conditions

CLABSI - Central Line Associated Bloodstream Infection

Interventions

Hemoglobin levelOTHER

Hb ≤ 9.6 g/dL

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with PICC line more than 48 hours, performed by Anesthesia Department from January 2023 to December 2024 Exclusion Criteria: * Incomplete data * Patient with reported colonization of PICC line * Patient with unintended position of PICC line * Patient with any other central venous catheter besides PICC line * Patient with previously reported as CLABSI

Locations (1)

Siriraj Hospital

Bangkok Noi, Bangkok, Thailand

Outcomes

Primary Outcomes

rate of CLABSI

incidence of CLABSI

Time frame: From January 2023 to December 2024

Secondary Outcomes

Study the risk factors related to CLABSI, including clinical factors, comorbidities, indication for PICC, and laboratory.

To evaluate potential risk factors for CLABSI, baseline demographic, clinical, and procedural characteristics will be collected at PICC line insertion and analyzed using two aggregated formats: continuous variables will be reported as means (with SD) or medians (with IQR): age (years), weight (kg), height (m), combined BMI (kg/m\^2), procedure duration (minutes), catheter indwelling time (days), hemoglobin (g/dL), and white blood cell counts (cells/µL). Categorical variables will be reported as percentages/proportions: sex, ICU admission, preprocedural antibiotics, procedure duration \<60 minutes, indwelling time ≤6 weeks, comorbidities (immunocompromised, hypertension, liver disease, diabetes, oncologic/hematologic malignancies), and insertion indications (TPN, CMT, prolonged IV meds, frequent blood sampling, vasopressors). All variables will be analyzed via regression to identify independent predictors of CLABSI.

Time frame: From January 2023 to December 2024

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.